{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T08:00:51Z","timestamp":1780992051784,"version":"3.54.1"},"reference-count":34,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.clml.2025.10.026","type":"journal-article","created":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T17:31:35Z","timestamp":1761931895000},"page":"e357-e366","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Salvage Autologous Stem Cell Transplantation Outcomes and The Use of Maintenance in Relapsed Multiple Myeloma: Real world evidence from the Canadian Myeloma Research Group Database"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8556-4926","authenticated-orcid":false,"given":"Rayan","family":"Kaedbey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4701-4285","authenticated-orcid":false,"given":"Christopher P.","family":"Venner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna","family":"Reece","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9398-2677","authenticated-orcid":false,"given":"Kevin","family":"Hay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Engin","family":"Gul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiandong","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arleigh","family":"McCurdy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael P.","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor H.","family":"Jimenez-Zepeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0786-7961","authenticated-orcid":false,"given":"Kevin","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hira","family":"Mian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha","family":"Louzada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Sebag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2706-8764","authenticated-orcid":false,"given":"Anthony","family":"Reiman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darrell","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Stakiw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rami","family":"Kotb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Aslam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Masih-Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debra","family":"Bergstrom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9990-2183","authenticated-orcid":false,"given":"Richard","family":"LeBlanc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2025.10.026_bib0001","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1182\/blood-2020-134538","article-title":"Early versus late autologous stem cell transplant in newly diagnosed multiple myeloma: long-term follow-up analysis of the IFM 2009 trial","volume":"136","author":"Perrot","year":"2020","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.clml.2025.10.026_bib0002","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1056\/NEJMoa2204925","article-title":"Triplet therapy, transplantation, and maintenance until progression in myeloma","volume":"387","author":"Richardson","year":"2022","journal-title":"N Engl J Med"},{"issue":"15_suppl","key":"10.1016\/j.clml.2025.10.026_bib0003","doi-asserted-by":"crossref","first-page":"8000","DOI":"10.1200\/JCO.2016.34.15_suppl.8000","article-title":"Upfront autologous stem cell transplantation (ASCT) versus novel agent-based therapy for multiple myeloma (MM): a randomized phase 3 study of the European Myeloma Network (EMN02\/HO95 MM trial)","volume":"34","author":"Cavo","year":"2016","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.clml.2025.10.026_bib0004","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/S1470-2045(21)00535-0","volume":"22","author":"Gay","year":"2021","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.clml.2025.10.026_bib0005","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.bbmt.2011.10.044","article-title":"Second autologous stem cell transplantation as salvage therapy for multiple myeloma: impact on progression-free and overall survival","volume":"18","author":"Jimenez-Zepeda","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"10.1016\/j.clml.2025.10.026_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3026(16)30049-7","article-title":"The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT\/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial","volume":"3","author":"Cook","year":"2016","journal-title":"Lancet Haematol"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2025.10.026_bib0007","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1182\/blood-2023-178835","article-title":"Salvage autologous transplant and lenalidomide maintenance versus continuous lenalidomide\/dexamethasone for relapsed multiple myeloma: long term follow up results of the randomized GMMG Phase III multicenter trial relapse","volume":"142","author":"Baertsch","year":"2023","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.clml.2025.10.026_bib0008","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1182\/blood.2024027342","article-title":"Salvage autologous transplant in relapsed multiple myeloma: long-term follow-up of the phase 3 GMMG ReLApsE trial","volume":"145","author":"Baertsch","year":"2025","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.clml.2025.10.026_bib0009","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1056\/NEJMoa1114138","article-title":"Lenalidomide maintenance after stem-cell transplantation for multiple myeloma","volume":"366","author":"Attal","year":"2012","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.clml.2025.10.026_bib0010","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1182\/blood.V116.21.37.37","article-title":"Phase III intergroup study of Lenalidomide versus Placebo maintenance therapy following single autologous hematopoietic stem cell transplantation (AHSCT) for multiple myeloma: CALGB 100104","volume":"116","author":"McCarthy","year":"2010","journal-title":"Blood"},{"issue":"29","key":"10.1016\/j.clml.2025.10.026_bib0011","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1200\/JCO.2017.72.6679","article-title":"Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis","volume":"35","author":"McCarthy","year":"2017","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2025.10.026_bib0012","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1182\/blood-2022-158219","article-title":"Real-world results of autologous stem cell transplantation in newly diagnosed patients with multiple myeloma: a multi-institutional report from the Canadian Myeloma Research Group (CMRG) database","volume":"140","author":"Cote","year":"2022","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.clml.2025.10.026_bib0013","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1038\/s41409-018-0216-3","article-title":"The efficacy of salvage autologous stem cell transplant among patients with multiple myeloma who received maintenance therapy post initial transplant","volume":"53","author":"Manjappa","year":"2018","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"10.1016\/j.clml.2025.10.026_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.clml.2025.10.026_bib0015","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.3324\/haematol.2018.194282","article-title":"Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX","volume":"103","author":"Dimopoulos","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2025.10.026_bib0016","doi-asserted-by":"crossref","first-page":"3192","DOI":"10.1182\/blood-2019-123527","article-title":"Efficacy and safety of Daratumumab, Bortezomib, and Dexamethasone (D-Vd) versus Bortezomib and Dexamethasone (Vd) in first relapse patients (pts) with multiple myeloma (MM): four-year update of Castor","volume":"134","author":"Weisel","year":"2019","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2025.10.026_bib0017","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/s41408-023-00797-8","article-title":"Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized phase 3 study","volume":"13","author":"Martin","year":"2023","journal-title":"Blood Cancer J"},{"issue":"3","key":"10.1016\/j.clml.2025.10.026_bib0018","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/S1470-2045(22)00019-5","article-title":"Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study","volume":"23","author":"Richardson","year":"2022","journal-title":"Lancet Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2025.10.026_bib0019","doi-asserted-by":"crossref","first-page":"7272","DOI":"10.1182\/blood-2022-163483","article-title":"Subcutaneous Daratumumab plus Pomalidomide and Dexamethasone (D-Pd) versus Pomalidomide and Dexamethasone (Pd) alone in patients with relapsed or refractory multiple myeloma (RRMM): overall survival results from the phase 3 Apollo study","volume":"140","author":"Dimopoulos","year":"2022","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2025.10.026_bib0020","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S1470-2045(21)00579-9","article-title":"Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study","volume":"23","author":"Usmani","year":"2022","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.clml.2025.10.026_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3026(24)00249-7","volume":"11","author":"Cook","year":"2024","journal-title":"Lancet Haematol"},{"issue":"18","key":"10.1016\/j.clml.2025.10.026_bib0022","doi-asserted-by":"crossref","first-page":"4706","DOI":"10.3390\/cancers13184706","article-title":"Carfilzomib, Lenalidomide, and dexamethasone followed by salvage autologous stem cell transplant with or without maintenance for relapsed or refractory multiple myeloma","volume":"13","author":"Baertsch","year":"2021","journal-title":"Cancers"},{"issue":"15_suppl","key":"10.1016\/j.clml.2025.10.026_bib0023","doi-asserted-by":"crossref","first-page":"8016","DOI":"10.1200\/JCO.2021.39.15_suppl.8016","article-title":"Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T cell therapy, in relapsed and refractory multiple myeloma: updated KarMMa results","volume":"39","author":"Anderson","year":"2021","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"10.1016\/j.clml.2025.10.026_bib0024","doi-asserted-by":"crossref","first-page":"8005","DOI":"10.1200\/JCO.2021.39.15_suppl.8005","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell (CAR-T) therapy, in relapsed\/refractory multiple myeloma (R\/R MM): updated results from CARTITUDE-1","volume":"39","author":"Usmani","year":"2021","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2025.10.026_bib0025","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1182\/blood-2022-162469","article-title":"KarMMa-2 cohort 2a: efficacy and safety of Idecabtagene Vicleucel in clinical high-risk multiple myeloma patients with early relapse after frontline autologous stem cell transplantation","volume":"140","author":"Usmani","year":"2022","journal-title":"Blood"},{"issue":"16_suppl","key":"10.1016\/j.clml.2025.10.026_bib0026","doi-asserted-by":"crossref","first-page":"8029","DOI":"10.1200\/JCO.2022.40.16_suppl.8029","article-title":"Biological correlative analyses and updated clinical data of ciltacabtagene autoleucel (cilta-cel), a BCMA-directed CAR-T cell therapy, in patients with multiple myeloma (MM) and early relapse after initial therapy: CARTITUDE-2, cohort B","volume":"40","author":"van de Donk","year":"2022","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.clml.2025.10.026_bib0027","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or Standard care in lenalidomide-refractory multiple myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2025.10.026_bib0028","doi-asserted-by":"crossref","first-page":"S569","DOI":"10.1016\/S2152-2650(24)01703-8","article-title":"MM-549 Ciltacabtagene Autoleucel vs standard of care in patients with functional high-risk multiple myeloma: CARTITUDE-4 subgroup analysis","volume":"24","author":"Costa","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"9","key":"10.1016\/j.clml.2025.10.026_bib0029","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat Med"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2025.10.026_bib0030","doi-asserted-by":"crossref","first-page":"3385","DOI":"10.1182\/blood-2023-182130","article-title":"Long-term efficacy and safety of Elranatamab monotherapy in the phase 2 Magnetismm-3 trial in relapsed or refractory multiple myeloma (RRMM)","volume":"142","author":"Tomasson","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.10.026_bib0031","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.8007","article-title":"Teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed\/refractory multiple myeloma (RRMM): updated efficacy and safety results from MajesTEC-1","author":"Nooka","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2025.10.026_bib0032","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1182\/blood-2021-147983","article-title":"Cevostamab monotherapy continues to show clinically meaningful activity and manageable safety in patients with heavily pre-treated relapsed\/refractory multiple myeloma (RRMM): updated results from an ongoing phase I study","volume":"138","author":"Trudel","year":"2021","journal-title":"Blood"},{"issue":"16_suppl","key":"10.1016\/j.clml.2025.10.026_bib0033","doi-asserted-by":"crossref","first-page":"8015","DOI":"10.1200\/JCO.2022.40.16_suppl.8015","article-title":"Efficacy and safety of talquetamab, a G protein-coupled receptor family C group 5 member D x CD3 bispecific antibody, in patients with relapsed\/refractory multiple myeloma (RRMM): updated results from MonumenTAL-1","volume":"40","author":"Minnema","year":"2022","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.clml.2025.10.026_bib0034","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1182\/bloodadvances.2022009435","article-title":"Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis","volume":"7","author":"Mazahreh","year":"2023","journal-title":"Blood Adv"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025042673?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025042673?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T07:44:43Z","timestamp":1780991083000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265025042673"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S2152265025042673"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2025.10.026","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Salvage Autologous Stem Cell Transplantation Outcomes and The Use of Maintenance in Relapsed Multiple Myeloma: Real world evidence from the Canadian Myeloma Research Group Database","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2025.10.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2025 Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}